BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22906080)

  • 1. Aggregated low-density lipoprotein induce impairment of the cytoskeleton dynamics through urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor in human vascular smooth muscle cell.
    Lugano R; Peña E; Badimon L; Padró T
    J Thromb Haemost; 2012 Oct; 10(10):2158-67. PubMed ID: 22906080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UPA promotes lipid-loaded vascular smooth muscle cell migration through LRP-1.
    Lugano R; Peña E; Casani L; Badimon L; Padró T
    Cardiovasc Res; 2013 Nov; 100(2):262-71. PubMed ID: 23812296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoproteins induce heat shock protein 27 dephosphorylation, oligomerization, and subcellular relocalization in human vascular smooth muscle cells.
    García-Arguinzonis M; Padró T; Lugano R; Llorente-Cortes V; Badimon L
    Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1212-9. PubMed ID: 20378850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4.
    Kiyan Y; Tkachuk S; Hilfiker-Kleiner D; Haller H; Fuhrman B; Dumler I
    J Mol Cell Cardiol; 2014 Jan; 66():72-82. PubMed ID: 24239845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain.
    Padró T; Peña E; García-Arguinzonis M; Llorente-Cortes V; Badimon L
    Cardiovasc Res; 2008 Jan; 77(1):211-20. PubMed ID: 18006454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tyrosine phosphatase SHP-2 controls urokinase-dependent signaling and functions in human vascular smooth muscle cells.
    Kiyan J; Haller H; Dumler I
    Exp Cell Res; 2009 Apr; 315(6):1029-39. PubMed ID: 19133257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-dependent human vascular smooth muscle cell adhesion requires selective vitronectin phosphorylation by ectoprotein kinase CK2.
    Stepanova V; Jerke U; Sagach V; Lindschau C; Dietz R; Haller H; Dumler I
    J Biol Chem; 2002 Mar; 277(12):10265-72. PubMed ID: 11756447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts.
    Kiyan J; Smith G; Haller H; Dumler I
    Biochem J; 2009 Oct; 423(3):343-51. PubMed ID: 19691446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggregated low-density lipoprotein induces LRP1 stabilization through E3 ubiquitin ligase CHFR downregulation in human vascular smooth muscle cells.
    Cal R; García-Arguinzonis M; Revuelta-López E; Castellano J; Padró T; Badimon L; Llorente-Cortés V
    Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):369-77. PubMed ID: 23241409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase receptor associates with myocardin to control vascular smooth muscle cells phenotype in vascular disease.
    Kiyan Y; Limbourg A; Kiyan R; Tkachuk S; Limbourg FP; Ovsianikov A; Chichkov BN; Haller H; Dumler I
    Arterioscler Thromb Vasc Biol; 2012 Jan; 32(1):110-22. PubMed ID: 22075245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin.
    Dumler I; Stepanova V; Jerke U; Mayboroda OA; Vogel F; Bouvet P; Tkachuk V; Haller H; Gulba DC
    Curr Biol; 1999 Dec 16-30; 9(24):1468-76. PubMed ID: 10607589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.
    Farris SD; Hu JH; Krishnan R; Emery I; Chu T; Du L; Kremen M; Dichek HL; Gold E; Ramsey SA; Dichek DA
    J Biol Chem; 2011 Jun; 286(25):22665-77. PubMed ID: 21536666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LDL-induced impairment of human vascular smooth muscle cells repair function is reversed by HMG-CoA reductase inhibition.
    Padró T; Lugano R; García-Arguinzonis M; Badimon L
    PLoS One; 2012; 7(6):e38935. PubMed ID: 22719992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator (uPA) promotes ezrin-mediated reorganization of the synaptic cytoskeleton in the ischemic brain.
    Merino P; Diaz A; Manrique LG; Cheng L; Yepes M
    J Biol Chem; 2018 Jun; 293(24):9234-9247. PubMed ID: 29720403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction.
    Kusch A; Tkachuk S; Haller H; Dietz R; Gulba DC; Lipp M; Dumler I
    J Biol Chem; 2000 Dec; 275(50):39466-73. PubMed ID: 10995743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease-mediated human smooth muscle cell proliferation by urokinase requires epidermal growth factor receptor transactivation by triple membrane signaling.
    Duru EA; Fu Y; Davies MG
    J Surg Res; 2014 Dec; 192(2):254-62. PubMed ID: 25082749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
    Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
    Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells.
    Hou Y; Okamoto C; Okada K; Kawao N; Kawata S; Ueshima S; Matsuo O
    Cardiovasc Res; 2007 Jul; 75(1):186-94. PubMed ID: 17382917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
    Yebra M; Goretzki L; Pfeifer M; Mueller BM
    Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.